A phase I dose-escalation study of the polyamine analog PG-11047 in patients with advanced solid tumors

ConclusionResults of this phase I trial suggest that PG-11047 can be safely administered to patients on the once weekly dosing schedule described. The manageable toxicity profile and high MTD determination provide a safety profile for further clinical studies, including those in combination with current chemotherapeutic agents.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research